


PRODUCT INFORMATION



MK2 Inhibitor IV

Item No. 14399

CAS Registry No.: 1314118-94-9
Formal Name: 5-(4-chlorophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide, monohydrochloride
Synonym: MK 25
MF: C₂₇H₂₅ClN₄O₂ • HCl
FW: 509.4
Purity: ≥95%
UV/Vis.: λ_{max}: 256, 312 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MK2 inhibitor IV is supplied as a crystalline solid. A stock solution may be made by dissolving the MK2 inhibitor IV in the solvent of choice, which should be purged with an inert gas. MK2 inhibitor IV is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of MK2 inhibitor IV in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF.

MK2 inhibitor IV is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, MK2 inhibitor IV should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. MK2 inhibitor IV has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Activation of the p38/mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) pathway has been implicated in promoting pro-inflammatory cytokine production and related inflammatory diseases. MK2 inhibitor IV is a highly selective, non-ATP competitive MK2 inhibitor with an IC₅₀ value of 0.11 μM.¹ MK2 inhibitor IV has been shown to inhibit pro-inflammatory cytokine secretion from the human THP-1 acute monocytic leukemia cell line, causing inhibition of LPS-stimulated TNF-α (IC₅₀ = 4.4 μM) and IL-6 (IC₅₀ = 5.2 μM) secretion.¹ It can also inhibit IL-1β-stimulated matrixmetalloprotease 13 secretion from the SW1353 chondrosarcoma cell line (IC₅₀ = 5.7 μM) and human primary chondrocyte cultures (IC₅₀ = 2.2 μM).¹

Reference

1. Huang, X., Shipps, G.W., Jr., Cheng, C.C., *et al.* Discovery and hit-to-lead optimization of non-ATP competitive MK2 (MAPKAPK2) inhibitors. *ACS Med. Chem. Lett.* **2**(8), 632-637 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/02/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM